Orbimed Advisors now owns 11.20% of Gracell Biotechnologies (GRCL)

Fintel reports that Orbimed Advisors has filed a Form 13D with the SEC disclosing ownership of 7.58 million shares of Gracell Biotechnologies Inc. (GRCL). This represents 11.2% of the company.

In their previous filing dated February 14, 2023, they declared 5.97 million shares and 8.80% of the company,
an increase in the number of shares of 27.01% and an increase in total ownership of 2.40% (calculated as current – previous ownership percentage).

Analyst price forecast suggests 596.89% upside

As of March 30, 2023, the one-year average price target for Gracell Biotechnologies was $12.82. The forecast ranges from a low of $7.07 to a high of $21.00. The average price target represents a 596.89% increase from its last reported closing price of $1.84.

Check out our ranking of the companies with the biggest upward price target.

Expected annual revenue for Gracell Biotechnologies is $0 million, a decrease of %. Projected annual non-GAAP EPS is -$0.59.

What is fund sentiment?

There are 52 funds or institutions reporting positions in Gracell Biotechnologies. This is a decrease of 1 owner(s) or 1.89% in the last quarter. Average portfolio weight of all funds dedicated to GRCL is 0.11%, an increase of 29.14%. The total number of shares held by institutions has decreased by 0.29% over the past three months to 31,832,000 shares.

What do major shareholders do?

Temasek Holdings holds 9,902,000 shares representing 14.63% ownership of the company. No change in the last quarter.

EcoR1 Capital holds 3,343,000 shares representing 4.94% ownership of the company. In its previous filing, the company said it held 1,921,000 shares, representing
a raise
of 42.53%. The company

increase

its portfolio allocation in GRCL of 28.16% during the last quarter.

Capital International holds 2,943,000 shares representing 4.35% ownership of the company. In its previous filing, the company stated that it holds 3,016,000 shares, representing
a decrease
2.50%. The company

decreases

its portfolio allocation in GRCL of 32.66% during the last quarter.

Great Point Partners holds 1,962,000 shares representing 2.90% ownership of the company. In its previous filing, the company said it held 449,000 shares, representing
a raise
of 77.12%. The company

increase

its portfolio allocation in GRCL of 154.09% in the last quarter.

EMRGX – EMERGING MARKETS GROWTH FUND INC Class M holds 1,336,000 shares representing 1.97% ownership of the company. In its previous filing, the company said it held 1,368,000 shares, representing
a decrease
2.36%. The company

decreases

its portfolio allocation in GRCL of 36.27% during the last quarter.

General information about Gracell Biotechnologies
(This description is provided by the company.)

Gracell Biotechnologies Inc. (

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.